Molecular genetics of B-precursor acute lymphoblastic leukemia
Open accessThe DOI matches its Crossref record; 126 of the 127 references it cites were found in a registry or an index.
Abstract
B-precursor acute lymphoblastic leukemia (B-ALL) is the most common childhood tumor and the leading cause of cancer-related death in children and young adults. The majority of B-ALL cases are aneuploid or harbor recurring structural chromosomal rearrangements that are important initiating events in leukemogenesis but are insufficient to explain the biology and heterogeneity of disease. Recent studies have used microarrays and sequencing to comprehensively identify all somatic genetic alterations in acute lymphoblastic leukemia (ALL). These studies have identified cryptic or submicroscopic genetic alterations that define new ALL subtypes, cooperate with known chromosomal rearrangements, and influence prognosis. This article reviews these advances, discusses results from ongoing second-generation sequencing studies of ALL, and highlights challenges and opportunities for future genetic profiling approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“BCP-ALL, which is characterized by a block in lymphoid differentiation leading to the accumulation of immature progenitor cells.37”
From PELI2 regulates early B-cell progenitor differentiation and related leukemia via the IL-7R expression (2023) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“org Volume 122 Number 10 October 2012 3409 such as imatinib mesylate (Gleevec) have transformed the treatment and outcome of patients with BCR-ABL1–positive leukemia (40, 41).”
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713 · cited 1×
“org Volume 122 Number 10 October 2012 3409 such as imatinib mesylate (Gleevec) have transformed the treatment and outcome of patients with BCR-ABL1–positive leukemia (40, 41).”
Yeoh, E.-J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00032-6 · Cited by 1,917 · cited 1×
“These approaches, coupled with candidate gene sequencing and integrated gene expression profiling (92), have identified a number of critical new targets of mutation in B-ALL that often involve genes that regulate lymphoid development, cell cycle, tumor suppression, and a variety of other key…”
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801 · cited 6×
“The nature and frequency of these CNAs are significantly associated with ALL subtype, with few lesions in MLL-rearranged ALL (17, 55) but 6–8 lesions per case in BCR-ABL1 and ETV6-RUNX1 ALL (33, 34).”
InfluentialSelf-citationCBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
Self-citationPui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422 · cited 2×
“Despite their high frequency of occurrence, PAX5 alterations are not associated with outcome in ALL (81, 95).”
Self-citation
Research works printed but not linked: 2
- Andersson AK, et al. Whole genome sequence anal- ysis of 22 MLL rearranged infant acute lympho- blastic leukemias reveals remarkably few somatic mutations: a report from the St. Jude Children's Research Hospital -Washington University Pedi- atric Cancer Genome Project. ASH Annual Meeting Abstracts. 2011;118:69.
- Mullighan, 2007, 110, 691
Cited by
Items 101–200 of 261
Prognostification of ALL by Cytogenetics
Hakeem, A., Shiekh, A. A., Bhat, G. M., & Lone, A. R. (2014) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-014-0483-0 · Cited by 18
“Appreciation of these submicroscopic genomic abnormalities and mutations is redefining the subclassification of ALL [44–50].”
BackgroundOverview on Aneuploidy in Childhood B-Cell Acute Lymphoblastic Leukemia
Panuciak, K., Nowicka, E., Mastalerczyk, A., Zawitkowska, J., Niedźwiecki, M., & Lejman, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108764 · Cited by 17
“For this reason, it seems beneficial to develop new targeted therapies, which would undoubtedly improve the results of treatment of patients [63,64,89–91].”
BackgroundFang, Q., Zhao, X., Li, Q., Li, Y., Liu, K., Tang, K., Wang, Y., Liu, B., Wang, M., Xing, H., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1180682 · Cited by 17
“somal alteration,[3] and genome-wide analyses”
Joo, E. J., Wasik, B. R., Parrish, C. R., Paz, H., Mühlenhoff, M., Abdel‐Azim, H., Groffen, J., & Heisterkamp, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-33873-2 · Cited by 18
CD9 predicts ETV6-RUNX1 in childhood B-cell precursor acute lymphoblastic leukemia
Blunck, C. B., Terra‐Granado, E., Noronha, E. P., Wajnberg, G., Passetti, F., Pombo‐de‐Oliveira, M. S., & Emerenciano, M. (2019) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2018.11.007 · Cited by 17
Federico, C., Brancato, D., Bruno, F., Coniglio, E., Sturiale, V., & Saccone, S. (2025) · Genes · doi:10.3390/genes16070780 · Cited by 17
“For instance, ETV6::RUNX1 is associated with a favorable prognosis, whereas KMT2A fusions or hypodiploidy are typically linked to adverse outcomes [112].”
Sharma, G., Boby, E., Thakur, N., Jain, A., Singh, J., Singh, A., Chattopadhyay, P., Bakhshi, S., Chopra, A., & Palanichamy, J. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.588101 · Cited by 16
“About 50% of B-ALL tumors exhibit genetic rearrangements among which translocations are most common (3).”
BackgroundGalectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia
Fei, F., Zhang, M., Tarighat, S. S., Joo, E. J., Yang, L., & Heisterkamp, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214359 · Cited by 16
Ghezali, L. A., Arbabian, A., Roudot, H., Brouland, J., Baran‐Marszak, F., Salvaris, E. J., Boyd, A., Drexler, H. G., Enyedi, Á., Letestu, R., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0556-7 · Cited by 16
“These oncoproteins activate distinct molecular oncogenic mechanisms, influence prognosis, and are widely used for the molecular classification of precursor-B ALL [30, 31].”
BackgroundHicks, C., Miele, L., Koganti, T., Young-Gaylor, L. D., Rogers, D., Vijayakumar, V., & MEGASON, G. C. (2013) · Cancer Informatics · doi:10.4137/cin.s11831 · Cited by 16
Genetically engineered mouse models of human B-cell precursor leukemias
Hauer, J., Borkhardt, A., Sánchez-García, I., & Cobaleda, C. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949137 · Cited by 18
Fregona, V., Bayet, M., & Gerby, B. (2021) · Cancers · doi:10.3390/cancers13215511 · Cited by 18
“Remarkably, Mullighan and colleagues demonstrated that more than half of the relapse ALL samples lacked some of the genomic copy number abnormalities (CNAs) present at the diagnosis and acquired new and distinct genetic lesions [66,75,76].”
BackgroundTebbi, C. K., Badiga, A., Sahakian, E., Powers, J. J., Achille, A. N., Patel, S. J., & Migone, F. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100279 · Cited by 14
Kaczmarska, A., Śliwa-Tytko, P., Zawitkowska, J., & Lejman, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126411 · Cited by 14
“Close to 20% of B-ALL cases showed gene rearrangements of CRL2, ABL1, JAK2, PDGFRB, JAK1, and JAK2, which activate kinase signaling [91].”
BackgroundETV6-RUNX1 + Acute Lymphoblastic Leukaemia in Identical Twins
Ford, A. M., & Greaves, M. F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_14 · Cited by 14
Su, H., Wang, M., Pang, X., Guan, F., Li, X., & Cheng, Y. (2021) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2021_60 · Cited by 14
Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities
Kourti, M., Aivaliotis, M., & Hatzipantelis, E. (2023) · Diagnostics · doi:10.3390/diagnostics13172748 · Cited by 14
“3) is very uncommon in patients with B-ALL and, despite its rarity, has been associated with extremely poor outcome [30].”
BackgroundWeeks, R. J., Ludgate, J. L., Mée, G. L., & Morison, I. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151341 · Cited by 13
“The mechanism by which these lymphoblasts have become abnormal is thought to involve multiple molecular events, including gene mutations and chromosomal translocations [5].”
BackgroundClinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia
Alexander, S. W. (2014) · Hematology · doi:10.1182/asheducation-2014.1.181 · Cited by 17
JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility
Lin, M., Nebral, K., Gertzen, C. G. W., Ganmore, I., Haas, O. A., Bhatia, S., Fischer, U., Kuhlen, M., Gohlke, H., Izraeli, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0459-z · Cited by 13
Zhong, Y., Beimnet, K., Alli, Z., Arnoldo, A., Kowalski, P. E., Somers, G. R., Hawkins, C. E., & Abdelhaleem, M. M. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.08.008 · Cited by 13
Madzio, J., Pastorczak, A. K., Sędek, Ł., Braun, M., Taha, J., Wypyszczak, K., Trelińska, J., Lejman, M., Muszyńska-Rosłan, K. M., Tomasik, B., et al. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22748 · Cited by 14
Chen, D., Camponeschi, A., Nordlund, J., Marincevic-Zuniga, Y., Abrahamsson, J., Lönnerholm, G., Fogelstrand, L., & Mårtensson, I. (2021) · Cancer Medicine · doi:10.1002/cam4.3928 · Cited by 12
Burmeister, T., Gröger, D., Gökbuget, N., Spriewald, B. M., Starck, M., Elmaagacli, A. H., Hoelzer, D. F., Keller, U. B., & Schwartz, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-42294-9 · Cited by 12
Hicks, C., Sitthi-Amorn, A., Douglas, J., Ramani, R., Miele, L., Vijayakumar, V., Karlson, C., Chipeta, J., & MEGASON, G. C. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s18180 · Cited by 14
BTK, NUTM2A, and PRPF19 Are Novel KMT2A Partner Genes in Childhood Acute Leukemia
Zerkalenkova, E., Lebedeva, S., Borkovskaia, A., Soldatkina, O., Plekhanova, O., Tsaur, G., Maschan, M. A., Maschan, A. A., Novichkova, G. A., & Olshanskaya, Y. V. (2021) · Biomedicines · doi:10.3390/biomedicines9080924 · Cited by 12
“They are commonly found in infant acute lymphoblastic leukemia (ALL)—up to 70–80% [2,3], and with less frequency in ALL or acute myeloid leukemia (AML) in a broader age range of older children or adults [4,5].”
BackgroundAdult Acute Lymphoblastic Leukemia: A Genetic Overview and Application to Clinical Practice
Jacobson, S., Tedder, M. L., & Eggert, J. (2016) · Clinical journal of oncology nursing · doi:10.1188/16.cjon.e147-e154 · Cited by 11
“E150 December 2016 • Volume 20, Number 6 • Clinical Journal of Oncology Nursing (Mullighan, 2012).”
BackgroundInfluentialChaber, R., Gurgul, A., Wróbel, G., Haus, O., Tomoń, A., Kowalczyk, J., Szmatoła, T., Jasielczuk, I., Rybka, B., Ryczan‐Krawczyk, R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187422 · Cited by 12
Zerkalenkova, E., Mikhaylova, E., Lebedeva, S., Illarionova, O., Байдун, Л. В., Kashpor, S. A., Osipova, E. Y., Maschan, M. A., Maschan, A., Novichkova, G. A., et al. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22915 · Cited by 10
“Translocations affecting KMT2A (former MLL) gene are associated with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).1 Such aberrations are generally rare and occur in approximately 6% of ALL and 3% of AML.2,3 However, in children, these alterations are much more common, and in infant leukemia…”
BackgroundInfluentialCentrosome Aberration Frequency and Disease Association in B-Acute Lymphoblastic Leukemia
Kerketta, L. S., Ghosh, K., Nadkarni, A. H., Madkaikar, M. R., & Vundinti, B. R. (2017) · In Vivo · doi:10.21873/invivo.11048 · Cited by 11
Haque, S., & Vaiselbuh, S. R. (2020) · Leukemia Research Reports · doi:10.1016/j.lrr.2020.100221 · Cited by 10
“Heterogeneity of relapsed ALL clones are distributed as; 8% same as diagnosis, 34% clonal evolution from diagnosis, 51% clonal evolution from a pre-leukemic clone, and 7% unrelated second leukemia [7].”
BackgroundIL-7 and IL-7R in health and disease: An update through COVID times
Fernandes, M. B., & Barata, J. T. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100940 · Cited by 10
Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL
Lejman, M., Włodarczyk, M., Zawitkowska, J., & Kowalczyk, J. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0709-y · Cited by 10
A ceRNA approach may unveil unexpected contributors to deletion syndromes, the model of 5q- syndrome
Arancio, W., Genovese, S. I., Bongiovanni, L., & Tripodo, C. (2015) · Oncoscience · doi:10.18632/oncoscience.261 · Cited by 9
“These rearrangements span from deletions, duplication, balanced and unbalanced translocations, to the gain or loss of whole chromosomes, which are often associated [1-8].”
BackgroundMoreno, D. A., Ribeiro, H. L., Laranjeira, A. B. A., Cruzeiro, G. A. V., Borges, K. S., Salomão, K. B., Ramalho, F. S., Yunes, J. A., Silva, C. L. A., Rego, E. M., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01813-w · Cited by 9
“Patients with acute lymphoblastic leukemia (ALL) with t(4;11)(q21; q23)/MLL-AF4 are characterized with poor prognosis, aggressive clinical features and even with current treatment strategies, 5-year survival remains low (15 to 35%) indicating the need for alternative therapies [11, 12, 15, 17].”
BackgroundActivating PAX gene family paralogs to complement PAX5 leukemia driver mutations
Hart, M. R., Anderson, D. J., Porter, C. C., Neff, T., Levin, M. G., & Horwitz, M. S. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007642 · Cited by 9
“Cancer genome sequencing has identified a wide diversity of mutations [8,9], such that no two ALL patients are likely to share identical mutational profiles.”
BackgroundIntroduction and Classification of Leukemias
Brown, G. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0810-4_1 · Cited by 11
Frondoside A potentiates the effects of conventional therapeutic agents in acute leukemia
Sajwani, F. H., Collin, P. D., & Adrian, T. E. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.11.002 · Cited by 9
Ehm, P. A. H., Bettin, B., & Jücker, M. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119467 · Cited by 10
A somatic UBA2 variant preceded ETV6-RUNX1 in the concordant BCP-ALL of monozygotic twins
Bang, B., Eisfeldt, J., Barbany, G., Harila-Saari, A., Heyman, M., Zachariadis, V., Taylan, F., & Nordgren, A. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005703 · Cited by 7
“addition, Tw1 carried a subclonal deletion of ETV6 in 6% of cells while Tw2 carried a 238 subclonal deletion of ETV6 and a t(1;12)(p13;p13),+der(1)t(1;12) in 44% of cells.”
BackgroundWill novel agents for ALL finally change the natural history?
Douer, D. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.10.006 · Cited by 8
Tebbi, C. K., Badiga, A., Sahakian, E., Arora, A. I., Nair, S., Powers, J. J., Achille, A. N., Jaglal, M. V., Patel, S. J., & Migone, F. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001845 · Cited by 8
Park, T. Y., Leiserson, M. D. M., Klau, G. W., & Raphael, B. J. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100099 · Cited by 9
Chiaretti, S., Jabbour, E. J., & Hoelzer, D. F. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.03.014 · Cited by 7
“Clinical Lymphoma, Myeloma & Leukemia May 2018 Good prognosis aberrations include t(12;21)/ETS variant 6 (ETV6)-Runt related transcription factor 1 (RUNX1) and high hyperdiploidy (51-65 chromosomes).”
BackgroundNovel clinical trials for pediatric leukemias: lessons learned from genomic analyses
Biondi, A., & Cazzaniga, G. (2013) · Hematology · doi:10.1182/asheducation-2013.1.612 · Cited by 7
Ouzounoglou, E., Dionysiou, D. D., & STAMATAKOS, G. S. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0264-5 · Cited by 8
“This choice has been made not only due to the high incidence rate of this subtype [16, 17], but also because of the substantial amount of related knowledge accumulated in literature.”
BackgroundLin, X., Liu, X., Zhang, Y., Li, N., Yang, Z., Fu, W., Lan, L., Zhang, H., & Dai, Y. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3832 · Cited by 7
“However, these genetic alterations are insufficient to fully explain the biology and heterogeneity of this disease (11).”
InfluentialTackling Acute Lymphoblastic Leukemia—One Fish at a Time
Sinha, A. A., Park, G., & Frazer, J. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215313 · Cited by 7
“Many subgroups are defined by translocations that create oncogenic fusion proteins that then transform B cell progenitors, such as the ”Philadelphia chromosome” (BCR-ABL1), ETV6-RUNX1, and TCF3-PBX1 [68].”
BackgroundBerry, N., Scott, R. J., Sutton, R., Law, T., Trahair, T. N., Dalla-Pozza, L., Ritchie, P., Barbaric, D., & Enjeti, A. K. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.01.051 · Cited by 7
Role of different aberrant cell signalling pathways prevalent in acute lymphoblastic leukemia
Gopal, P. K., Paul, M., & Paul, S. (2014) · Biologia · doi:10.2478/s11756-014-0428-y · Cited by 7
“Genomewide gene analysis array using microarray, candidate gene and second generation sequencing have also provided a detailed light on the genetic basis of B-ALL development (Mullighan 2012).”
MethodMoafi, A., Zojaji, A., Salehi, R., Dorcheh, S. N., & Rahgozar, S. (2017) · Cellular and Molecular Biology · doi:10.14715/cmb/2017.63.8.4 · Cited by 7
Tao, J., Zhang, X., Lancet, J. E., Bennett, J. M., Cai, L., Papenhausen, P. R., Moscinski, L. C., & Zhang, L. (2014) · Cancer Genetics · doi:10.1016/j.cancergen.2014.10.001 · Cited by 7
“About 25% of B-ALL patients have other unclassified genetic abnormalities (2,3,11,12).”
BackgroundD’Amico, G., Starace, R., Lastra, M. D., Marimpietri, D., Dander, E., Morandi, F., & Airoldi, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115380 · Cited by 7
“Among the various subtypes, the most common is caused by an abnormal clonal proliferation of B cell progenitors, while in the remaining cases, there is the uncontrolled proliferation of mature B cells [50].”
Gutiérrez-Camino, Á., Caron, M., Richer, C., Fuchs, C., Illarregi, U., Poncelet, L., St-Onge, P., Bataille, A. R., Tremblay-Dauphinais, P., López-López, E., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031477 · Cited by 6
“Hyperdiploid cases and patients harboring the ETV6::RUNX1 rearrangement together represent about half of B-ALL cases and are associated with good prognosis [1,3].”
BackgroundRamírez‐Chiquito, J. C., Villegas-Ruíz, V., Vera, I., Sánchez-Cruz, I., Frías‐Soria, C. L., Palacios, M. Y., Antonio-Andrés, G., Rubio-Portillo, A. E., Velasco‐Hidalgo, L., Pérezpeña-Díazconti, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020744 · Cited by 6
Zeng, M. N., Ma, W. L., & Zheng, W. (2016) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2016.07.009 · Cited by 6
Delafoy, M., Balducci, E., Simonin, M., Pinton, A., Charbonnier, G., Courtois, L., Lhermitte, L., Gillet, C., Féroul, M., Touzart, A., et al. (2025) · HemaSphere · doi:10.1002/hem3.70154 · Cited by 5
“ALL, 28 were rare in infant/toddler T ‐”
Polito, A. N., Polimeno, R., & Kanduc, D. (2017) · International Journal of Pediatrics and Child Health · doi:10.12974/2311-8687.2017.05.01.4 · Cited by 5
Chang, Y.-H., Yang, Y., Chen, C., & Chen, H. (2015) · Europe PMC (PubMed Central) · Cited by 6
Lepe-Zúñiga, J. L., Jerónimo-López, F. J., & Hernández-Orantes, J. G. (2017) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2016.12.002 · Cited by 5
Nakka, P., Archer, N. P., Xu, H. Y., Lupo, P. J., Raphael, B. J., Yang, J. J. J., & Ramachandran, S. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0360 · Cited by 5
“Leukemogenesis can also be triggered via the HOXregulatory pathway through translocations involving the MLL gene (41, 42).”
BackgroundSitthi-Amorn, A., Herrington, B. L., MEGASON, G. C., Pullen, J., Gordon, C., Hogan, S. M., Koganti, T., & Hicks, C. (2015) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s17049 · Cited by 6
Forat-Yazdi, M., Hosseini-Biouki, F., Salehi, J. A., Neámatzadeh, H., Dehshiri, R. M., Sadri, Z., Ghanizadeh, F., Sheikhpour, R., & Zare‐Zardini, H. (2016) · PubMed Central · Cited by 5
The biological role of lncRNAs in the acute lymphocytic leukemia: An updated review
Almanghadim, H. G., Karimi, B., poursalehi, N., Sanavandi, M., pourfardin, S. A., & Ghaedi, K. (2023) · Gene · doi:10.1016/j.gene.2023.148074 · Cited by 5
Poncelet, L., Richer, C., Gutiérrez-Camino, Á., Veres, T., & Sinnett, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093956 · Cited by 4
“Patients carrying ETV6::RUNX1 translocation account for approximately 20% of cases and have a good prognosis although with some potential for relapse [2,3] while patients presenting with the TCF3::PBX1 fusion gene, which account for approximately 3–5% of cases, have a poorer prognosis [4,5].”
Using Cytogenetic Rearrangements for Cancer Prognosis and Treatment (Pharmacogenetics)
Li, M. M., Ewton, A. A., & Smith, J. L. (2013) · Current Genetic Medicine Reports · doi:10.1007/s40142-013-0011-9 · Cited by 5
Offenmüller, S., Ravindranath, Y., Goyette, G. W., Kanakapalli, D., Miller, K. S., Brecht, I. B., & Zolk, O. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25011 · Cited by 4
“B-precursor ALL (B-ALL)—despite the high rate of cure—remains one of the leading causes of cancer-related death among children [2].”
BackgroundWang, Y. M., Mo, J. Q., Kuo, D. J., & Wong, V. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-227400 · Cited by 4
Jain, N., Hartert, K., Tadros, S., Fiskus, W. C., Havránek, O., Ma, M.-C. J., Bouska, A. C., Heavican, T., Kumar, D., Deng, Q., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/170605 · Cited by 4
Xu, Y., Zhou, Q., Wang, X., Zhang, A., Qi, W., Li, Y., Zheng, C., Guan, J., Sun, T., Li, J., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.284041 · Cited by 3
Saluja, S., Ganguly, S., Singh, J., Jain, A., Sharma, G., Chaudhary, S., Pethusamy, K., Chattopadhyay, P., Chopra, A., Singh, A., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102403 · Cited by 3
“…rearranged B-ALL, which are already known to be associated with poor survival outcome, were taken together as ‘poor prognostic molecular category (poor risk) ’ and ETV6-RUNX1 along with NKST (no known sentinel translocation) were clubbed in ‘good prognostic category (good risk) ’ [14,17,21 – 24].”
Suzuki, A., Shigehiro, T., Hirakawa, M., Hirano, R., Tamai, M., Akahane, K., Okamoto, K., Takayanagi, H., Terashima, Y., Ueha, S., et al. (2026) · Blood · doi:10.1182/blood.2025031521 · Cited by 3
Cory, S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501277 · Cited by 3
“Many “master genes” are also proto-oncogenes or tumor suppressors (28).”
BackgroundPeterson, J. F., Smoley, S. A., Luoma, I. M., Pitel, B. A., Rice, C. S., Demasi, J. C. B., Vasmatzis, G., Smadbeck, J. B., Yang, T., Greipp, P. T., et al. (2019) · Journal of Hematopathology · doi:10.1007/s12308-019-00355-x · Cited by 3
TdT-positive Infiltrate in Inflamed Pediatric Kidney
Dunlap, J. B., Cascio, M. J., Stacey, X., Click, S., & Troxell, M. L. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000828 · Cited by 3
Taylan, F., Bang, B., Öfverholm, I. I., Tran, A.-N., Heyman, M. M., Barbany, G., Zachariadis, V., & Nordgren, A. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.293548 · Cited by 3
DeKoter, R. P., & Gibson, P. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.09019-6 · Cited by 3
Leons, G. K., Sharma, P., Gupta, S. K., Gupta, R., Rani, L., Gajendra, S., Roy, A., & Sahoo, R. K. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30546 · Cited by 3
Moreta, V., & Freire, D. A. R. (2025) · Bionatura journal : · doi:10.70099/bj/2025.02.01.15 · Cited by 2
A pseudotime-dependent TWAS framework identifies disease genes along cell developmental paths
Cao, R., Li, C., Cui, E., Spector, L. G., Raduski, A. R., Anderson, N., Guan, W., Gordon, P., Im, C., & Yang, T. (2026) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2026.100634 · Cited by 2
“18,19 Given that the B cell subtype accounts for the majority of ALL cases, its well-characterized developmental pathway from hematopoietic stem cells to mature plasma cells presents a clear modeling opportunity, particularly for the B cell stages pre-sent in accessible samples such as peripheral…”
B-Cell Acute Lymphoblastic Leukemia in a Child with Down Syndrome and High-Risk Genomic Lesions
Albu, C.-C., Bica, F., Nan, L., Bubulac, L., Bogdan-Andreescu, C. F., Şerbănică, I., Poalelungi, C.-V., Cadâr, E., Banateanu, A. M., & Burcea, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090704 · Cited by 2
“ALL is the most common pediatric leukemia, accounting for approximately 75–80% of cases worldwide [1–3].”
Acute Lymphoblastic Leukemia: Genetic Events and Molecular Signatures
Hu, Y. (2014) · American Journal of Biomedical Sciences · doi:10.5099/aj140400238 · Cited by 2
Insights of Acute Lymphoblastic Leukemia with Development of Genomic Investigation
Xu, H. Y., & Shu, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7717-8_21 · Cited by 2
Single-cell mass cytometry and machine learning predict relapse in childhood leukemia
Sarno, J., & Davis, K. L. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1472057 · Cited by 2
“Five-year survival rates exceed 85% with modern therapies, however survival following relapse remains a significant problem and leading cause of cancer-related mortality in childhood.(1) Predicting patients at risk for relapse involves a combination of clinical characteristics, prognostic somatic mutations and early r…”
BackgroundCritical Roles of Non-coding RNAs in Acute Lymphoblastic Leukemia
Gavgani, M. M., Nargesian, M., & Ghorbian, . (2018) · Gene Cell and Tissue · doi:10.5812/gct.83297 · Cited by 2
“Many studies have reported recurrent cytogenetic abnormalities in B-ALL including the fusion of ETS variant 6 (ETV6) and RUNX1 genes (ETV6-RUNX1), BCR-ABL, mixed lineage leukemia (MLL) rearrangements, and the fusion protein of E2A and PBX1 genes (E2APBX1), which account for about 30 percent of cases (24).”
BackgroundWafa, A., Jarjour, R. A., Alolabi, D., Liehr, T., Hamdan, O., Melo, J. B., Carreira, I. M., Othman, M. A. K., & Achkar, W. A. (2020) · Molecular Cytogenetics · doi:10.1186/s13039-020-00512-3 · Cited by 2
Zhang, X. (2021) · Springer eBooks · doi:10.1007/978-3-030-73227-1_15 · Cited by 2
Genetic Profiling of Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
Akın, D. F., Erdoğan, B. D., Öner, D. A., Mahmud, A., Taşdelen, S., Kürekçi, E., Akar, N., & Özdağ, H. (2022) · Journal of Pediatric Genetics · doi:10.1055/s-0041-1742246 · Cited by 2
“11, 12, 16, 17 Although there The present study used targeted NGS and gene expression analysis performed with qRT-PCR to analyze mutations in ZAP70, TSLP, JAK2, CRLF2, IKZF1, PAX5, EBF1, CREBBP, FOXO3A, RB1, ZNRF1, NR3C1, NF1, ERG, VLA-4, and CXCR4.”
BackgroundMethodAkinci, N. (2022) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.14744/semb.2022.89646 · Cited by 2
“At present, we know that 75% of ALL cases have evidence of molecular rearrangements.[21] The reasons for low rate of genetic abnormalities found in our study might be the inclusion of very old cases and the technical deficiencies at that time.”
BackgroundUnder the surface: scratching the acute lymphoblastic leukemia niche
Gower, M., & Tikhonova, A. N. (2022) · Haematologica · doi:10.3324/haematol.2022.282191 · Cited by 2
Real-time genomic characterization of pediatric acute leukemia using adaptive samplingPreprint
Geyer, J. K., Opoku, K. B., Lin, J., Ramkissoon, L. A., Mullighan, C. G., Bhakta, N. H., Alexander, T., & Wang, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.11.617690 · Cited by 2
Self-citationPediatric High Risk Leukemia — Molecular Insights
Gowda, C. S., Francis, O. L., Ding, Y., Shiraz, P., Payne, K. J., & Dovat, S. (2015) · InTech eBooks · doi:10.5772/61247 · Cited by 2
“Figure 1 and Table 1 show cytogenetic abnormalities seen in ALL [6, 7].”
BackgroundAlghasi, A., Pedram, M., Saki, N., Salari, F., Jaseb, K., Asnafi, A. A., Yousefi, H., Malehi, A. S., Norozi, F., Moeinzadeh, L., et al. (2015) · Iranian Journal of Blood and Cancer · Cited by 1
Amaki, J., Matsushita, H., Kitamura, Y., Nagao, R., Murayama, H., Kojima, M., & Ando, K. (2016) · Leukemia Research Reports · doi:10.1016/j.lrr.2016.04.001 · Cited by 1
“5% of pediatric B-ALL cases [5].”
Lepe-Zuniga, J. L., Jerónimo-López, F. J., & Hernández-Orantes, J. G. (2017) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.1016/j.bmhime.2016.12.001 · Cited by 1
A rare case of B cell lymphoblastic leukemia with inv(7)(p15q34) with review of literature.
Andrew, B., Orazi, A., Guar, S., Tonk, V. S., Ghafouri, S. R., & Padilla, O. (2021) · Leukemia Research Reports · doi:10.1016/j.lrr.2021.100250 · Cited by 1
“normalities including t(1;19)-E2A/PBX1,t(12;21)-ETV/ CBFα, and t (9;22)-BCR/ ABL [2].”
BackgroundBiondi, A., Scrideli, C. A., & Cazzaniga, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-19674-9_41 · Cited by 1
Meng, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809967-4.00008-9 · Cited by 2
Identification of a novel MEF2C::SS18L1 fusion in childhood acute B-lymphoblastic leukemia
Chen, C., Wang, J., Kang, M., Wu, P., Zhu, L., Fang, Y., & Yao, X. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05846-8 · Cited by 1
“About 75% of B-ALL patients exhibit abnormal chromosomal numbers or translocations (Mullighan 2012), which can generate fusion genes, including ETV6::RUNX1, TCF3::PBX1, BCR::ABL1, MLL -related fusion genes, etc. (Harrison and Foroni 2002; Onciu 2009).”
BackgroundSkhoun, H., Fessikh, M. E., Khattab, M., Mchich, B., Agadr, A., Abilkassem, R., Dakka, N., Flatters, D., Camproux, A., Ouzzif, Z., et al. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10968-2 · Cited by 1
“Acute lymphoblastic leukemia (ALL) represents the most recurrent childhood tumor and the main cause of pediatric cancer deaths (Mullighan 2012).”
Metadata
- Authors
- Mullighan, C. G.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Corresponding author
- Mullighan, Charles G.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-01
- Volume
- 122
- Issue
- 10
- Pages
- 3407-3415
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3461902
- OpenAlex
- W2146473098
- Cited by
- 247
- References
- 127
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 12 · 2023: 10 · 2022: 15 · 2021: 17 · 2020: 22 · 2019: 21 · 2018: 15 · 2017: 30 · 2016: 32 · 2015: 16 · 2014: 20 · 2013: 17 · 2012: 1
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- American Society of Hematology
- St. Jude Children's Research Hospital
- American Lebanese Syrian Associated Charities (38105)
- Children’s Oncology Group
- Stand Up To Cancer
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- B-cell precursor acute lymphoblastic leukemia, somatic alterations, chromosomal rearrangements, aneuploidy, prognosis, leukemogenesis, genetic profiling, childhood cancer
- MeSH terms
- Adult, Animals, B-Lymphocytes, Child, Clone Cells, Hematopoietic Stem Cells, Humans, Neoplasm Proteins, Prognosis, Risk, Translocation, Genetic, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Oncogene Proteins, Fusion, Mice, Knockout, Cell Lineage, Genetic Predisposition to Disease, Gene Expression Profiling, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.